47 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 47 of 47 clinical reviews.
A clinical guide to Aetna (CVS Health) coverage for Vyleesi (bremelanotide), including prior authorization criteria, step therapy requirements, formulary tier, appeal strategies, and manufacturer savings options.
A clinical and insurance guide to Anthem (Elevance Health) coverage of Vyleesi (bremelanotide) for HSDD, including prior authorization criteria, step therapy requirements, appeal strategies, and cost alternatives.
Find out whether Humana covers Vyleesi (bremelanotide) for HSDD, what prior-authorization criteria apply, how formulary tiers work, and exactly how to appeal a denial in 2024.
Kaiser Permanente coverage details for Vyleesi (bremelanotide), including formulary status, prior authorization requirements, step therapy, appeal options, and cost-saving alternatives for HSDD treatment.
Evidence-based protocols for switching between Vyleesi (bremelanotide) and flibanserin (Addyi), off-label testosterone, or other HSDD treatments, including washout timing, efficacy expectations, and safety considerations.
Bremelanotide (Vyleesi) has no FDA approval, clinical trial data, or guideline-supported dosing for adolescents aged 12, 17. This article explains why, reviews the adult evidence, and outlines what pediatric safety gaps remain.
No clinical trial data supports bremelanotide (Vyleesi) use in adolescents aged 12-17. Review the pharmacology, regulatory status, and safety considerations for this age group.
Evidence-based dosing guide for Vyleesi (bremelanotide) in adult women ages 30-49 with HSDD. Covers the FDA-approved 1.75 mg subcutaneous dose, injection timing, frequency limits, and clinical trial data from RECONNECT.
A clinician-grade review of every known and theoretical drug-drug interaction with bremelanotide (Vyleesi), including oral bioavailability effects, cardiovascular overlaps, and melanocortin pathway crosstalk.
Evidence-based guide to bremelanotide (Vyleesi) dosing adjustments for patients with hepatic impairment, including pharmacokinetic data, FDA labeling, and clinical recommendations.
Evidence-based guide to bremelanotide (Vyleesi) use in adults 65 and older, covering dose adjustments, safety considerations, renal decline, and clinical monitoring for geriatric patients with HSDD.
Evidence-based monitoring guide for bremelanotide (Vyleesi) in premenopausal women aged 30 to 49 with HSDD. Covers blood pressure checks, nausea management, injection-site reactions, melanocyte screening, and follow-up timelines.
Clinical guidance on bremelanotide (Vyleesi) overdose management, symptoms of accidental excess dosing, expected adverse effects, and when to seek emergency care.
Bremelanotide (Vyleesi) has no FDA-approved pediatric dosing for children under 12. Learn why this drug is restricted to premenopausal adult women, what the FDA label says, and what parents should know.
A clinical review of bremelanotide (Vyleesi) real-world evidence from registries, post-market surveillance, and observational studies for HSDD in premenopausal women.
Current regulatory status of bremelanotide (Vyleesi) across the United States, European Union, Canada, and United Kingdom, including approval history, mechanism of action, and clinical evidence from the RECONNECT trials.
A guide to bremelanotide (Vyleesi) safety in women ages 18 to 29, covering nausea rates, blood pressure effects, contraceptive interactions, fertility considerations, and dosing from the RECONNECT trials.
A guide to bremelanotide (Vyleesi) safety in premenopausal women aged 30 to 49, covering adverse-event rates from the RECONNECT trials, blood-pressure warnings, nausea management, and long-term use considerations.
A guide to bremelanotide (Vyleesi) safety for adults aged 50 to 64, covering cardiovascular risk, nausea, blood pressure changes, polypharmacy, and perimenopause considerations.
A clinician-level review of bremelanotide (Vyleesi) safety and efficacy in patients with autoimmune conditions, including lupus, RA, MS, and Sjögren syndrome, with primary-literature citations.
A clinical-depth review of bremelanotide (Vyleesi) and cancer risk signals, covering FDA labeling, RECONNECT trial data, melanoma warnings, and practical prescribing guidance for premenopausal women with HSDD.
A deep dive into bremelanotide (Vyleesi) cardiovascular effects, blood pressure changes, long-term safety data from RECONNECT, and clinical guidance for patients with cardiac risk factors.
A clinical deep-dive into bremelanotide (Vyleesi) and cognitive function. Learn what the RECONNECT trials found, what melanocortin receptors have to do with cognition, and what patients should expect.
An evidence-based comparison of compounded bremelanotide and FDA-approved Vyleesi for HSDD, covering pharmacology, safety, efficacy data from RECONNECT, dosing, and how to choose between options.
Vyleesi runs $850 to $950 per carton (about $215-$240 per dose), versus $800-$1,000 for brand Addyi or $30-$80 for generic flibanserin.
A GRADE-level appraisal of bremelanotide (Vyleesi) for hypoactive sexual desire disorder in premenopausal women, including RECONNECT trial data, effect sizes, safety profile, and prescribing guidance.
A clinical deep-dive into bremelanotide (Vyleesi) hair and skin changes, including transient hyperpigmentation, flushing mechanisms, melanocortin pharmacology, and what the RECONNECT trial data actually show.
The complete history of bremelanotide (Vyleesi), from its origins as a melanocortin analog to FDA approval for hypoactive sexual desire disorder in premenopausal women.
A clinician-level review of bremelanotide (Vyleesi) and liver function impact, covering hepatotoxicity data from RECONNECT, ALT/AST monitoring thresholds, and FDA labeling requirements for premenopausal women with HSDD.
A physician-level explanation of how bremelanotide (Vyleesi) activates melanocortin-4 receptors in the CNS to restore sexual desire in premenopausal women with HSDD.
A breakdown of bremelanotide's (Vyleesi) effects on mood, anxiety, depression, and emotional well-being, drawn from the RECONNECT trials and post-market safety data.
A clinician-level review of bremelanotide (Vyleesi) microdosing protocols, standard FDA-approved dosing, RECONNECT trial data, and what off-label dose reduction means in practice for premenopausal women with HSDD.
Evidence-based guidance on Vyleesi (bremelanotide) missed-dose scenarios, including timing windows, dose adjustments, and when to contact your prescriber. prepared by the HealthRX.com Editorial Team.
When do Vyleesi patents expire? A clinical breakdown of bremelanotide patent coverage, Hatch-Waxman exclusivity, and the realistic timeline for a generic or biosimilar alternative.
Bremelanotide (Vyleesi) is not approved for children under 12. This guide covers FDA pediatric labeling, melanocortin receptor physiology in children, and what to do if accidental exposure occurs.
A source-checked review of Vyleesi pharmacokinetics, including current FDA values for bioavailability, Tmax, Cmax, volume of distribution, metabolism, half-life, excretion, organ impairment, and oral-drug interactions.
Why bremelanotide (Vyleesi) stops working or never works, and what clinicians and patients can do about it. Evidence-based troubleshooting from the RECONNECT trials with dosing, timing, and combination strategies.
A clinician-level guide to the bremelanotide (Vyleesi) pre-surgery hold window, covering FDA labeling, cardiovascular pharmacology, anesthesia interactions, and practical perioperative management protocols.
A guide to bremelanotide (Vyleesi) safety during pregnancy and breastfeeding, covering mechanism of action, FDA labeling, reproductive toxicology data, and practical clinical guidance.
A deep dive into bremelanotide (Vyleesi) and renal function: pharmacokinetics, clinical trial safety data, FDA labeling guidance, and practical prescribing advice for patients with kidney concerns.
Evidence-based guidance on safely restarting bremelanotide (Vyleesi) after acute illness, including dose timing, contraindications, and pharmacology from the RECONNECT trial and FDA prescribing information.
A clinician-level review of bremelanotide (Vyleesi) safety signals, FDA actions, post-marketing data, and the melanocortin mechanism behind HSDD treatment in premenopausal women.
A clinician-level review of how bremelanotide (Vyleesi) affects sexual desire, arousal, and distress in premenopausal women with HSDD, based on RECONNECT trial data and FDA-approved prescribing information.
A clinician-level review of how bremelanotide (Vyleesi) affects sleep architecture, including melanocortin receptor pharmacology, clinical trial data from RECONNECT, and practical dosing guidance for women with HSDD.
Everything clinicians and patients need to know about bremelanotide (Vyleesi) storage temperatures, shelf life, auto-injector stability, and what to do if a dose is compromised.
A week-by-week guide to bremelanotide (Vyleesi) covering what to expect in the first month: dosing, side effects, efficacy timelines, and clinical trial data.
Complete clinical guide to bremelanotide (Vyleesi) dosing for young adults aged 18 to 29, including injection technique, timing, side-effect management, and RECONNECT trial data.
LegitScript certification
Verify HealthRX.comHealthRX.com is a platform connecting patients with independent licensed healthcare providers and pharmacies. Those providers deliver medical care and pharmacies dispense medication. Prescriptions are issued only when clinically appropriate. Payment does not guarantee a prescription.
Compounded medications are not FDA-approved. The FDA does not review them for safety, effectiveness, or quality. Individual results vary.
Website information is educational and is not a substitute for personalized medical advice, diagnosis, or treatment. Consult your licensed healthcare provider.